124 related articles for article (PubMed ID: 20450431)
21. Immunohistochemical demonstration of thyrotropin (TSH)-receptor in normal and diseased human thyroid tissues using monoclonal antibody against recombinant human TSH-receptor protein.
Mizukami Y; Hashimoto T; Nonomura A; Michigishi T; Nakamura S; Noguchi M; Matsukawa S
J Clin Endocrinol Metab; 1994 Aug; 79(2):616-9. PubMed ID: 8045985
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters.
Shuja S; Cai J; Iacobuzio-Donahue C; Zacks J; Beazley RM; Kasznica JM; O'Hara CJ; Heimann R; Murnane MJ
Thyroid; 1999 Jun; 9(6):569-77. PubMed ID: 10411119
[TBL] [Abstract][Full Text] [Related]
23. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue.
Brönnegård M; Törring O; Böös J; Sylven C; Marcus C; Wallin G
J Clin Endocrinol Metab; 1994 Aug; 79(2):384-9. PubMed ID: 8045952
[TBL] [Abstract][Full Text] [Related]
24. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.
Ringel MD; Anderson J; Souza SL; Burch HB; Tambascia M; Shriver CD; Tuttle RM
Mod Pathol; 2001 Apr; 14(4):289-96. PubMed ID: 11301345
[TBL] [Abstract][Full Text] [Related]
25. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease.
Kim WB; Han SM; Kim TY; Nam-Goong IS; Gong G; Lee HK; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2004 Jun; 60(6):719-25. PubMed ID: 15163336
[TBL] [Abstract][Full Text] [Related]
26. Coexistent thyroid nodules in patients with graves' disease: What is the frequency and the risk of malignancy?
Shi HH; McHenry CR
Am J Surg; 2018 Nov; 216(5):980-984. PubMed ID: 30049435
[TBL] [Abstract][Full Text] [Related]
27. Thyroid carcinoma risk in patients with hyperthyroidism and role of preoperative cytology in diagnosis.
Gul K; Di Ri Koc A; Ki Yak G; Ersoy PE; Ugras NS; Ozdemi D; Ersoy R; Cakir B
Minerva Endocrinol; 2009 Dec; 34(4):281-8. PubMed ID: 20046157
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma.
Kato M; Maeta H; Kato S; Shinozawa T; Terada T
Mod Pathol; 2000 Oct; 13(10):1060-5. PubMed ID: 11048798
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.
Ain KB; Taylor KD; Tofiq S; Venkataraman G
J Clin Endocrinol Metab; 1997 Jun; 82(6):1857-62. PubMed ID: 9177396
[TBL] [Abstract][Full Text] [Related]
30. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues.
Marti U; Ruchti C; Kämpf J; Thomas GA; Williams ED; Peter HJ; Gerber H; Bürgi U
Thyroid; 2001 Feb; 11(2):137-45. PubMed ID: 11288982
[TBL] [Abstract][Full Text] [Related]
31. A patient with an autonomously functioning thyroid nodule with papillary adenocarcinoma associated with Graves' hyperthyroidism.
Tsuboi M; Shigemasa C; Ueta Y; Yoshida A; Kobayashi K; Mori T; Mashiba H
Clin Nucl Med; 1995 Nov; 20(11):985-8. PubMed ID: 8565381
[TBL] [Abstract][Full Text] [Related]
32. Evidence for Somatostatin receptor 2 in thyroid tissue.
Druckenthaner M; Schwarzer C; Ensinger C; Gabriel M; Prommegger R; Riccabona G; Decristoforo C
Regul Pept; 2007 Jan; 138(1):32-9. PubMed ID: 16996150
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein e expression in anaplastic thyroid carcinoma.
Ito Y; Takano T; Miyauchi A
Oncology; 2006; 71(5-6):388-93. PubMed ID: 17690558
[TBL] [Abstract][Full Text] [Related]
34. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
35. Sodium iodide symporter and pendrin expression in human thyroid tissues.
Mian C; Lacroix L; Alzieu L; Nocera M; Talbot M; Bidart JM; Schlumberger M; Caillou B
Thyroid; 2001 Sep; 11(9):825-30. PubMed ID: 11575851
[TBL] [Abstract][Full Text] [Related]
36. Evidence for processing of compact insoluble thyroglobulin globules in relation with follicular cell functional activity in the human and the mouse thyroid.
Gérard AC; Denef JF; Colin IM; van den Hove MF
Eur J Endocrinol; 2004 Jan; 150(1):73-80. PubMed ID: 14713282
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of DEHAL1 expression in thyroid pathologies.
Krause K; Karger S; Gimm O; Sheu SY; Dralle H; Tannapfel A; Schmid KW; Dupuy C; Fuhrer D
Eur J Endocrinol; 2007 Mar; 156(3):295-301. PubMed ID: 17322488
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
39. GLUT1 glucose transporter expression in benign and malignant thyroid nodules.
Haber RS; Weiser KR; Pritsker A; Reder I; Burstein DE
Thyroid; 1997 Jun; 7(3):363-7. PubMed ID: 9226204
[TBL] [Abstract][Full Text] [Related]
40. CD98 expression is decreased in papillary carcinoma of the thyroid and Hashimoto's thyroiditis.
Anderson CE; Graham C; Herriot MM; Kamel HM; Salter DM
Histopathology; 2009 Dec; 55(6):683-6. PubMed ID: 19922591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
